跳至主要内容
临床试验/NCT06249451
NCT06249451已完成不适用

SAB-Support-Study: Can Checklist-based Phone Calls Improve the Quality of Staphylococcus Aureus Bacteraemia (SAB) Management

University Medicine Greifswald1 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2024年1月22日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
124
试验地点
1
主要终点
SOP adherence, calculated as a sum score per patient with the following 8 parameters:

研究概览

简要总结

The main objective of this study is to investigate whether checklist-based close telephone consultation and process surveillance for S. aureus bacteraemia (SAB) can improve adherence to our in-house SAB-guidelines (prospective quality- improvement group).

In addition, the effects of telephone consultation on the clinical outcome of patients will be examined.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥ 18 years
  • Inpatient treatment at the University Medicine Greifswald university hospital
  • First diagnosis of SAB in hospital

排除标准

  • SAB already known before admission
  • Palliative management within 48 hrs after SAB diagnosis
  • Death within 48 hrs after SAB diagnosis
  • Hospital discharge within 48hrs after SAB diagnosis

结局指标

主要结局

SOP adherence, calculated as a sum score per patient with the following 8 parameters:

时间窗: Hospital admission until hospital discharge (no later than day 90 after diagnosis)

1. Drawing of follow-up blood cultures 2-3 days after start of adequate antibiotic therapy 2. Early source control (removal of infected material or drainage of an abscess ≤ 72 hrs) 3. Adequate search for SAB focus and metastatic manifestations 4. TEE in patients with clinical indications (within 4 days of SAB diagnosis) 5. Early start of specific therapy after receipt of results via phone call (≤12 hrs) 6. Adequate dosage of antibiotic 7. Sufficient duration of therapy (at least 14 d for uncomplicated bacteremia and 28 d for complicated bacteremia) 8. Combination therapy with Rifampicin or Fosfomycin, when indicated

次要结局

  • Time to specific antimicrobial treatment according to guidelines concerning agent and duration(Hospital admission until hospital discharge (no later than day 90 after diagnosis))
  • Time to negativity of follow up blood cultures(Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis))
  • Time till TEE is performed (when indicated)(Hospital admission until hospital discharge (no later than day 90 after diagnosis))
  • Length of hospital stay after SAB diagnosis(Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis))
  • In-hospital mortality (all patients)(Hospital admission until hospital discharge (no later than day 90 after diagnosis))
  • In-hospital mortality (because of SAB complications)(Hospital admission until hospital discharge (no later than day 90 after diagnosis))
  • Hospital readmission until day 90 after SAB diagnosis (all patients)(Day of SAB diagnosis until day 90 after diagnosis)
  • 90-day mortality because of SAB complications(Day of SAB diagnosis until day 90 after diagnosis)
  • Hospital readmission until day 30 after SAB diagnosis (all patients)(Day of SAB diagnosis until day 30 after diagnosis)
  • Hospital readmission until day 30 after SAB diagnosis (because of SAB complications)(Day of SAB diagnosis until day 30 after diagnosis)
  • Relapse of bacteremia until day 90 after diagnosis(Day of SAB diagnosis until day 90 after diagnosis)
  • Hospital readmission until day 90 after SAB diagnosis (because of SAB complications)(Day of SAB diagnosis until day 90 after diagnosis)
  • 90-day all-cause mortality(Day of SAB diagnosis until day 90 after diagnosis)
  • Quality of discharge summary (documentation and treatment plan), calculated as a sum score(Hospital admission until hospital discharge (no later than day 90 after diagnosis))
  • Infectious diseases consultation, when indicated (yes/no)(Hospital admission until hospital discharge (no later than day 90 after diagnosis))

研究者

发起方
University Medicine Greifswald
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验